252 related articles for article (PubMed ID: 19350237)
1. In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study.
Forrer F; Chen J; Fani M; Powell P; Lohri A; Müller-Brand J; Moldenhauer G; Maecke HR
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1443-52. PubMed ID: 19350237
[TBL] [Abstract][Full Text] [Related]
2. An approach for conjugation of (177) Lu- DOTA-SCN- Rituximab (BioSim) & its evaluation for radioimmunotherapy of relapsed & refractory B-cell non Hodgkins lymphoma patients.
Thakral P; Singla S; Yadav MP; Vasisht A; Sharma A; Gupta SK; Bal CS; ; Malhotra A
Indian J Med Res; 2014 Apr; 139(4):544-54. PubMed ID: 24927340
[TBL] [Abstract][Full Text] [Related]
3. Preparation and radiolabeling of a lyophilized (kit) formulation of DOTA-rituximab with ⁹⁰Y and ¹¹¹In for domestic radioimmunotherapy and radioscintigraphy of non-Hodgkin's lymphoma.
Gholipour N; Jalilian AR; Khalaj A; Johari-Daha F; Yavari K; Sabzevari O; Khanchi AR; Akhlaghi M
Daru; 2014 Jul; 22(1):58. PubMed ID: 25074720
[TBL] [Abstract][Full Text] [Related]
4. Impact of DOTA-Chelators on the Antitumor Activity of
Wojdowska W; Karczmarczyk U; Balog L; Sawicka A; Pöstényi Z; Kovács-Haász V; Polyák A; Laszuk E; Mikołajczak R; Garnuszek P
Cancer Biother Radiopharm; 2020 Oct; 35(8):558-562. PubMed ID: 32255676
[No Abstract] [Full Text] [Related]
5. Combination of
Repetto-Llamazares AHV; Malenge MM; O'Shea A; Eiríksdóttir B; Stokke T; Larsen RH; Dahle J
Eur J Haematol; 2018 Oct; 101(4):522-531. PubMed ID: 29993152
[TBL] [Abstract][Full Text] [Related]
6. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
Griffiths GL; Govindan SV; Sharkey RM; Fisher DR; Goldenberg DM
J Nucl Med; 2003 Jan; 44(1):77-84. PubMed ID: 12515879
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric analysis of 177Lu-DOTA-rituximab in patients with relapsed/refractory non-Hodgkin's lymphoma.
Yadav MP; Singla S; Thakral P; Ballal S; Bal C
Nucl Med Commun; 2016 Jul; 37(7):735-42. PubMed ID: 26974315
[TBL] [Abstract][Full Text] [Related]
8. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
[TBL] [Abstract][Full Text] [Related]
9. Standardization of Procedures for the Preparation of (177)Lu- and (90)Y-labeled DOTA-Rituximab Based on the Freeze-dried Kit Formulation.
Wojdowska W; Karczmarczyk U; Maurin M; Garnuszek P; Mikołajczak R
Curr Radiopharm; 2015; 8(1):62-8. PubMed ID: 25506704
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution and kinetics of (131)I-labelled anti-CD20 MAB IDEC-C2B8 (rituximab) in relapsed non-Hodgkin's lymphoma.
Scheidhauer K; Wolf I; Baumgartl HJ; Von Schilling C; Schmidt B; Reidel G; Peschel C; Schwaiger M
Eur J Nucl Med Mol Imaging; 2002 Oct; 29(10):1276-82. PubMed ID: 12271407
[TBL] [Abstract][Full Text] [Related]
11. High treatment efficacy by dual targeting of Burkitt's lymphoma xenografted mice with a (177)Lu-based CD22-specific radioimmunoconjugate and rituximab.
Weber T; Bötticher B; Mier W; Sauter M; Krämer S; Leotta K; Keller A; Schlegelmilch A; Grosse-Hovest L; Jäger D; Haberkorn U; Arndt MA; Krauss J
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):489-98. PubMed ID: 26341366
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response?
Sharkey RM; Brenner A; Burton J; Hajjar G; Toder SP; Alavi A; Matthies A; Tsai DE; Schuster SJ; Stadtmauer EA; Czuczman MS; Lamonica D; Kraeber-Bodere F; Mahe B; Chatal JF; Rogatko A; Mardirrosian G; Goldenberg DM
J Nucl Med; 2003 Dec; 44(12):2000-18. PubMed ID: 14660727
[TBL] [Abstract][Full Text] [Related]
13. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
14. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non-Hodgkin's lymphoma: a Children's Oncology Group study.
Cooney-Qualter E; Krailo M; Angiolillo A; Fawwaz RA; Wiseman G; Harrison L; Kohl V; Adamson PC; Ayello J; vande Ven C; Perkins SL; Cairo MS;
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5652s-5660s. PubMed ID: 17875803
[TBL] [Abstract][Full Text] [Related]
15. Validation of 64Cu-DOTA-rituximab injection preparation under good manufacturing practices: a PET tracer for imaging of B-cell non-Hodgkin lymphoma.
Natarajan A; Arksey N; Iagaru A; Chin FT; Gambhir SS
Mol Imaging; 2015; 14():. PubMed ID: 25762106
[TBL] [Abstract][Full Text] [Related]
16. Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.
Gopal AK; Press OW; Wilbur SM; Maloney DG; Pagel JM
Blood; 2008 Aug; 112(3):830-5. PubMed ID: 18502830
[TBL] [Abstract][Full Text] [Related]
17. Preparation & in vitro evaluation of ⁹⁰Y-DOTA-rituximab.
Kameswaran M; Pandey U; Dash A; Samuel G; Venkatesh M
Indian J Med Res; 2016 Jan; 143(1):57-65. PubMed ID: 26997015
[TBL] [Abstract][Full Text] [Related]
18. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
19. Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma.
Dahle J; Repetto-Llamazares AH; Mollatt CS; Melhus KB; Bruland OS; Kolstad A; Larsen RH
Anticancer Res; 2013 Jan; 33(1):85-95. PubMed ID: 23267131
[TBL] [Abstract][Full Text] [Related]
20. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
Weiden PL; Breitz HB
Crit Rev Oncol Hematol; 2001 Oct; 40(1):37-51. PubMed ID: 11578915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]